114
Participants
Start Date
October 31, 2006
Primary Completion Date
June 30, 2008
Study Completion Date
August 31, 2008
NM283 plus Peg-IFNα-2a
200 mg QD 180 µg QW
Atlanta
Fairfax
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY